Zyus Cannabis Research Focused on Benefits and Side-Effects
Saskatchewan Licensed Producer Fights Cash Flow, Bad Press – LPC
Zyus Life Sciences Inc. seems like any other medical cannabis startup in Canada. The Saskatchewan-based company received its Processing Licence from Health Canada last December. Its state-of-the-art Innovation Place facility is still under construction – for the most part. Yet one thing may set Zyus cannabis research apart from other companies: its founder.
Brent Zettl has already shown he can bring a cannabis company from conception to maturity. He founded CanniMed Therapeutics, a company he left after Aurora Cannabis acquired it for $1.1 billion. Three days later, he founded Zyus . Zettl’s goal is to make a “transformational impact” on medicine through Zyus cannabis research into cannabis-based drugs.
“Cannabinoid formulations have the potential to make very large changes in the medical space, the pharmaceutical space,” Zettl said. “It’s almost disruptive.”
He hopes that Zyus cannabis research will find alternatives to opiods for pain relief. He calls that class of drugs a failure.
“There’s a conviction that there’s something there,” he said. (Please see below for link to full article.) “Nobody can really pinpoint what that could be or what that is at this stage. And that’s what we want to do. It’s a space we’ll focus on.”
Zyus Cannabis Research Just What the Doctor Ordered – LPC
Zyus cannabis research plans is exactly what is needed – not just in Canada, but around the world. The Canadian Medical Association Journal (CMAJ) has openly questioned the risks and benefits of cannabis. However, it hasn’t been a witchhunt – just an honest request for more research. Indeed, several scientists from Canada and the US said that lack of cannabis research poses a danger to public health. In doctors’ offices – the front lines of healthcare – many patients still find it difficult to get a cannabis prescription. Once again, it’s not because doctors see cannabis as “evil” – though cannabis has certain had its share of bad press. They just want to have a full understanding of the drug, as they do any drug they prescribe.
Zyus cannabis research hopes to find those answers.
In the meantime, Zyus will have to find investors. Clinical trials can run into the hundreds of millions of dollars. However, the Zyus cannabis research program will likely be on the low end of those numbers given that it is somewhat known and is natural rather than lab-invented.
Zyus also hopes to get its Sales (Medical) Licence this summer, which will generate cash. In the meantime, its facility can also be used to produce other extracts.
“That’s why the ethanol (extraction) plant is good to start with, to generate some business,” Zettl said.
This editorial content from the LPC News Team provides analysis, insight, and perspective on current news articles. To read the source article this commentary is based upon, please click on the link below.
